The National Pharmaceutical Council (NPC) submitted feedback to the Institute for Clinical and Economic Review's (ICER) request for comment as it looks to update its value assessment framework. NPC in its comments proposed a "collaborative and transparent model development process." "NPC also […]
ICER Plans Review of Acute Migraine Treatments
The Institute for Clinical and Economic Review (ICER) on Friday, June 7, announced plans to assess the comparative clinical effectiveness and value of acute migraine treatments. According to a press release, the organization will review Biohaven's rimegepant, Allergan's ubrogepant and Eli Lilly's […]
Report: ICER Seeing Rising Influence as Pricing Debates Continue
The Institute for Clinical and Economic Review (ICER) continues to gain traction in the drug pricing discussion as a growing number of stakeholders look to the organization for drug pricing benchmarks, according to a Managed Care magazine report. According to the report, ICER has a full slate this […]
ICER: Zolgensma Price is ‘Positive Outcome’
The Institute for Clinical and Economic Review (ICER) said Novartis' decision to price its recently-approved spinal muscular atrophy (SMA) drug, Zolgensma, at $2.1 million was a "positive outcome." The Food and Drug Administration (FDA) approved Zolgensma on Friday, May 24. According to a press […]
ICER to Again Use hēRo3 for Evidence Review
The Institute for Clinical and Economic Review (ICER) will conduct another evidence review with the web-based hēRo3 platform, making this its second review with the modeling solution. Gerry Oster, PAI managing partner and practice lead, says ICER's decision to use the software confirms the […]
ICER Releases Report on DMD Treatments
The Institute for Clinical and Economic Review on Wednesday, May 22, released a draft evidence report for two gene therapies and a corticosteroid for the treatment of Duchenne muscular dystrophy (DMD). According to a press release, the report looks at Sarepta's gene therapies, eteplirsen and […]
ICER Announces New Cloud-Based Tools
The Institute for Clinical and Economics Review (ICER) announced Monday, May 20, that it is developing two new tools aimed at streamlining stakeholders' ability to examine the organization's "entire body of work" to bolster decision-making. ICER made the announcement during the International […]
ICER Says J&J’s Spravato is Overpriced
Johnson & Johnson's new therapy to treat resistant depression, Spravato, is overpriced, according to the Institute for Clinical and Economic Review (ICER), though it could provide a "comparable, small, or substantial net health benefit" for patients. According to a FiercePharma report, the […]
ICER, IPD Announce New Analytics Partnership
The Institute for Clinical and Economic Review (ICER) will leverage IPD Analytics' (IPD) data and insights to bolster its reviews of "high-impact, high-cost therapies" as part of a new collaborative effort, the organizations announced last week. The initiative was announced Thursday, May 9. IPD […]
Novartis’ Zolgensma About to Hit Market with Record Price Tag
Novartis' new gene therapy for the treatment of spinal muscular atrophy (SMA) is soon to hit the market with an expected price of roughly $2 million, the Wall Street Journal reports. While the drugmaker has not yet set the price of Zolgensma, according to the report, executives say the health […]
